TRUADVICE’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$1.1M Sell
1,835
-195
-10% -$100K 0.43% 65
2023
Q2
$1.06M Sell
2,030
-68
-3% -$28.5K 0.39% 73
2023
Q1
$831K Buy
2,098
+729
+53% +$246K 0.33% 80
2022
Q4
$490K Sell
1,369
-1
-0.1% -$355 0.26% 79
2022
Q3
$483K Buy
1,370
+1
+0.1% +$317 0.27% 72
2022
Q2
$419K Buy
+1,369
New +$411K 0.22% 88

Other funds holding LLY

TRUADVICE's LLY Position: Q3 2023 in Review

TRUADVICE reduced its Eli Lilly (LLY) stake by 9.6% in Q3 2023, selling an estimated $100K and leaving 1,835 shares worth $1.1M. The position accounts for 0.43% of the portfolio, ranked #65.

TRUADVICE first reported a position in LLY in Q2 2022 and has held it in 6 quarters since. 2,974 funds tracked by Wall St. Rank hold LLY as of Q3 2023.

  • TRUADVICE held 1,835 shares of Eli Lilly worth $1.1M as of Q3 2023.
  • TRUADVICE sold 195 Eli Lilly shares in Q3 2023, an estimated $100K.
  • Eli Lilly made up 0.43% of TRUADVICE's portfolio in Q3 2023, its #65 holding.
  • TRUADVICE first reported a position in Eli Lilly in Q2 2022 and has held it in 6 quarters since.
  • 2,974 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2023.

Based on TRUADVICE's 13F filing for Q3 2023, filed 13 Nov 2023.